PD‐1 inhibitor monotherapy was associated with a 2% thrombocytopenia rate; PD‐1/PD‐L1 inhibitor with chemotherapy had 6% higher thrombocytopenia risk.29 Here, PDCD1 is linked to Thrombocytopenia.